AOBiome - Transforming human health through the restoration of Ammonia-Oxidizing Bacteria

AOBiome Therapeutics Reports Positive Efficacy Results from Phase 2b Clinical Trial of Ammonia Oxidizing Bacteria (AOB) for the Treatment of Acne Vulgaris

First-in-Class Therapy Demonstrates Statistically Significant 2-Point Reduction (p=0.03) in Investigator’s Global Assessment (IGA)

No Treatment Related Adverse Events Observed

Read More


AOBiome is a Boston and San Francisco based biotech company focused on transforming human health through products that restore ammonia-oxidizing bacteria (AOBs) which current hygiene practices have stripped from the modern microbiome. Founded in 2013 by MIT Chemical Engineer David Whitlock and Patients Like Me founder Jamie Heywood along with co-founders Hilly Thompson and Lenny Barshack. The company is developing a novel class of therapeutics to improve skin health, hypertension, and other systemic conditions. AOBs convert ammonia to nitrite, an anti-microbial compound, and nitric oxide, a well-documented signaling molecule in the inflammatory process. AOBiome also owns the Mother Dirt branded line of consumer biome-friendly products targeted at restoring and maintaining the delicate balance of the skin biome.

Read More

Therapeutic Product Pipeline

  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Mild to Moderate Acne
  • Hypertension
  • Allergic Rhinitis
  • Pruritis/Eczema


"Why do horses roll around in the dirt?"

This question asked in the context of the microbiome has led to the discovery of the evolutionary role of AOBs. Founder David Whitlock's curiosity and nontraditional methods not only discovered the link between AOBs and human health, but also the methods to re-introduce them into the modern microbiome - even if that meant giving up showering for a while…

Read More


Nitric oxide is an important signaling molecular involved in many physiological and pathological processes. Nitric oxide was named "Molecular of the Year" by the American Association for the Advancement of Science and has been shown to have a significant role in vasodilation amongst other pathways. The Nitrosomonas bacteria being studied by AOBiome consume ammonia and produce nitric oxide, providing an effective delivery mechanism for this crucial molecule.

Read More


Conditions like acne, eczema, rosacea, and peanut allergies are not evolutionary in nature, but rather recent additions to the health lexicon. Children now sit at peanut free tables at school, a phenomenon unfamiliar to lunchrooms of previous generations. Even more troubling is the recent rise of Alpha-gal, an allergic reaction to meat.



In support of our mission, we have developed beauty and hygiene products that support the skin microbiome. As part of this process, we have developed strict criteria for ingredient selection, formulation, packaging, and manufacturing in addition to our trademarked "Biome Friendly" assay.

Shop Now

White House launches the National Microbiome Initiative.

Learn More

Recent News

April 23, 2018
AOBiome Therapeutics Expands Clinical-Stage Pipeline, Initiates Phase 2 Clinical Trial for Episodic Migraine
January 4, 2018
AOBiome Therapeutics Appoints Todd Krueger as Chief Executive Officer
October 19, 2017
AOBiome Therapeutics Reports Positive Efficacy Results from Phase 2b Clinical Trial of Ammonia Oxidizing Bacteria (AOB) for the Treatment of Acne Vulgaris